The macrophage-derived cytokine interleukin-1 (IL-1) can provide a second signal with antigen to elicit production of interleukin-2 (IL-2) by helper T cells. The pathway(s) involved remains controversial, with protein kinase C and cyclic AMP (cAMP) invoked as possible second messengers. In the murine thymoma EL4.E1, IL-1 could synergize with the phosphoinositide pathway, because the cells made higher levels of IL-2 in the presence of IL-1 than could be induced by phorbol ester plus calcium ionophore alone. IL-1 is unlikely to act through a sustained increase in cAMP in these cells because it did not raise cAMP levels detectably and because IL-1 and forskolin had opposite effects on IL-2 gene expression. Inducible expression of a transfected reporter gene linked to a cloned fragment of the murine IL-2 gene promoter was initially increased by IL-1 costimulation, implying that IL-1 can increase the rate of transcription of IL-2. The minimal promoter elements required for IL-1 responsiveness were located within 321 bp of the IL-2 RNA cap site, and further upstream sequences to -2800 did not modify this response. IL-1 costimulation resulted in enhanced activity of both an inducible NF-KB-like factor and one of two distinct AP-1-like factors that bind to IL-2 regulatory sequences. Neither was induced, however, by IL-1 alone. Another AP-1-like factor and NFAT-1, while inducible in other cel types, were expressed constitutively in the EL4.E1 cells and were unaffected by IL-1. These results are discussed in terms of the combinatorial logic of IL-2 gene expression.
Interleukin-1 (IL-1) is a potent mediator of cellular function that is produced primarily by activated macrophages (19) , and a role for IL-1 in T-cell activation has been demonstrated in a number of experimental systems (7, 8, 25) . In vitro, IL-1 synergizes with mitogenic lectins or anti-T-cell receptor (TcR) antibodies to induce expression of interleukin 2 (IL-2) and IL-2 receptor a-chain genes (13, 18, 44) . In these roles, IL-1 can be replaced by tumor-promoting phorbol esters (e.g., 12-0-tetradecanoylphorbol 13-acetate [TPA]) (11) . As IL-1 was known to provide a necessary, antigennonspecific signal for T-cell activation (9) , this apparent equivalence with TPA initially suggested that its action might result from activation of protein kinase C (28) . However, IL-1 does not promote phosphoinositide hydrolysis or cause protein kinase C translocation to an active membranebound form (1) . It therefore seems unlikely that its role is to augment the low levels of diacylglycerol produced by TcRmediated phosphoinositide breakdown. More recently, it has been demonstrated that IL-1 treatment of the human T-cell leukemia line Jurkat causes increased production of two protein kinase C cofactors, phosphatidylserine and diacylglycerol, the latter from hydrolysis of membrane phosphatidylcholine (23, 34) . However, because Jurkat lacks conventional IL-1 receptors (IL-lRs) (34) , the significance of these results for other T cells is unknown.
The studies that have reported a costimulatory role for IL-1 have usually demonstrated this effect on cells suboptimally stimulated with mitogenic lectins (13, 15, 18, 44) . Several laboratories have obtained results that call into doubt the notion that IL-1 is necessary at all for the high-level production of IL-2 when the TcR signal is optimized. We have shown that when fresh splenic T cells produce IL-2 in response to TPA and the calcium ionophore A23187, their response is both independent of and insensitive to added IL-1 (35, 36) . Lichtman et al. (21) have obtained similar results with a panel of cloned antigendependent THi cell lines stimulated with an anti-CD3 monoclonal antibody. Two other groups have shown that longterm TH1 (IL-2-producing) lines may lack IL-iRs altogether (14, 20) . Thus, these systems do not provide access to any unique pathway through which IL-1 may act.
Recent data suggest, however, that a requirement for IL-1 may reflect the developmental status of a T cell. These differences are most apparent in induction of IL-2 expression, a response subject to complex regulation (16, 27, 32) . Mature TcR+ thymocytes resemble peripheral T cells in their insensitivity to IL-1 when they are stimulated to produce IL-2 in response to TPA plus A23187. These chemical proxies for mediators of the phosphatidylinositol bisphosphate hydrolysis pathway may be able to induce IL-2 expression in all mature T cells, for they can also elicit high-level responses in most fresh peripheral CD8+ cells (24) , cells which generally do not express IL-2 mRNA in response to either antigen or mitogenic lectins. In contrast, however, immature TcRdouble-negative thymocytes do not make IL-2 in response to TPA and A23187 at all unless IL-1 is present (35, 36) . Thus, these immature thymocytes differ from their more mature descendents in two important aspects of their IL-2 inductive signal requirements. First, in these cells, phosphoinositide pathway agonists are insufficient to activate IL-1 expression. Second, they possess a pathway allowing IL-1 effects to synergize with phosphoinositide pathway mediators.
Here we report that the cloned murine thymoma EL4.E1 possesses characteristics of both immature and mature IL-2 producers. Like mature T cells, it can respond to phorbol ester and ionophore alone. In addition, it possesses a trait normally associated with immature thymocytes, namely, responsiveness to IL-1 as a costimulus with TPA plus A23187. We have used these cells to explore the mechanism by which the synergy between IL-1 and TPA plus A23187 occurs.
MATERIALS AND METHODS
Reagents. TPA and A23187 were from Sigma or Calbiochem. They were dissolved in dimethyl sulfoxide to final concentrations of 10 ,ug/ml and 0.37 mg/ml, respectively, and stored in small samples at -20°C. Recombinant human and mouse IL-la (IL-1) was purchased from Genzyme. The specific activity, as reported by the supplier, was 108 U/mg. Cells. EL4.E1, a mouse IL-2-producing thymoma cell line (originally donated by V. Paetkau, University of Alberta), and the human T-cell leukemic line Jurkat (generously provided by G. Crabtree, Stanford University) were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 p.M 2-mercaptoethanol, and antibiotics.
Plasmids. The series of pIL2-CAT plasmids containing varying lengths of the mouse IL-2 gene 5' DNA linked to the bacterial gene for chloramphenicol acetyltransferase (CAT) has been described in detail (30) . Briefly, cloned fragments of the IL-2 gene 5'-flanking region, all terminating 3' at +45 (in the 5' untranslated region), were ligated to the CAT gene from pTK-CAT in the vector pSP65 (Promega). They are designated pIL2(-X), where X is the 5'-terminal nucleotide, relative to the IL-2 transcriptional start site, that is present in the construct. All plasmids were purified in CsC1-ethidium bromide density gradients before use.
Transfections and CAT assays. Transfection of logarithmically growing cells was by DEAE-dextran facilitation as described elsewhere (30) . In short, cells were washed in serum-free Dulbecco modified Eagle medium with 10 mM N-2-hydroxylethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.0) (DME/H) and then suspended at 107/ml in a transfection cocktail containing 250 ,ug of DEAE-dextran (molecular weight, 2 x 106) per ml, 0.1 mM chloroquine, and 10 ,ug of supercoiled plasmid DNA per ml, all in DME/H. After incubation for 30 to 60 min at 37°C in 7% C02, cells were pelleted, washed, and plated into 4 to 12 identical cultures.
Approximately 20 h after plating, cells were stimulated with TPA and A23187 at final concentrations of 10 and 37 ng/ml, respectively. These dosages were previously determined to be optimal for both IL-2 mRNA expression and secretion over 18 to 20 h in the population overall. Some of the cells also received IL-1 to the indicated concentrations. Human recombinant IL-la was found to be as effective as the mouse version on ELA.E1 cells and was used in most experiments.
Cells were harvested after various times of stimulation, and extracts from equivalent numbers of cells were assayed for CAT activity in a 5-h assay as described previously (29) .
RNA analysis. Cytoplasmic RNA was extracted by the method of Favaloro et al. (12) . The RNA from equivalent cell numbers was electrophoresed in denaturing 1% agaroseformaldehyde gels, stained with acridine orange to visualize the rRNA, and then blotted onto nylon membranes (Nytran; Schleicher & Schuell). The RNA was fixed to the membrane by baking at 80°C for 60 min. Hybridization probes were generated by random priming of cDNAs for mouse IL-2 (46) and mouse skeletal a-actin (S. Sharp and N. Davidson, unpublished data) as described elsewhere (30) . Hybridizations were carried out for 20 h at 42°C in 5 x SSPE-50% formamide-0.2% sodium dodecyl sulfate (SDS)-5 x Denhardt solution-10% dextran sulfate. Filters were washed three times at room temperature for 1 min each in 2x SSC(SSC is 0.15 M NaCl prus 0.015 M sodium citrate-0.2% SDS-0.05% sodium pyrophosphate, followed by two 30-min washes at 680C in 0.2x SSC-0.1% SDS-0.05% sodium pyrophosphate. Filters were exposed to film at -700C with an intensifying screen, and autoradiograms in the linear response range were densitometrically scanned. The amount of IL-2 mRNA was normalized with respect to the actin signal. cAMP determination. EL4.E1 cells were resuspended in medium at a concentration of 1.2 x 106/ml and were stimulated at 37°C as indicated in Table 2 . Cell extracts were assayed for cyclic AMP (cAMP) by using a competition binding assay (RPA.509; Amersham) as described elsewhere (T. J. Novak and E. V. Rothenberg, Proc. Natl. Acad. Sci. USA, in press). Extracts were acetylated before assay to increase sensitivity. Nuclear extracts. Nuclear proteins were extracted according to published procedures (6, 8; G. Crabtree, personal communication) from cells that had been stimulated for 3 to 4 h under the conditions described for Fig. 4 and Table 3 . Proteins extracted by either method gave similar results in gel mobility shift assays, and the data presented in Table 4 were obtained by using both types of extraction protocols.
Extracts were stored at -80°C until use.
Gel mobility shift assay. Mobility shift assays were carried out essentially as described elsewhere (3), with minor modifications. Synthetic double-stranded oligonucleotides were end labeled by filling in with either 35S-or 32P-labeled dTTP and dATP. For binding assays, 2.5 to 5.0 ,ug of nuclear protein was incubated for 15 min at 250C with -0.1 ng of probe in the presence of a nonspecific competitor, usually 0.5 jig of poly(dI -dC) for NF-KB, 0.25 to 0.5 p.g of poly(dI dC) for AP-1D and AP-1p, or 2.5 to 10 ,ug of poly(dA * dT) for NFAT-1.
Complexes were separated from free probe by electrophoresis through 8% acrylamide gels which were cast and run in low-ionic-strength buffer. Gels were dried and exposed to film at -70°C with intensifying screens. For experiments with 35S-labeled probes, gels were fixed in Amplify (Amersham) and complexes were detected by fluorography. (20 U/ml), and forskolin (10 FLM) . Confirmation of the inhibitory effects of forskolin at the RNA level is presented by Novak and Rothenberg (in press).
b Titer in supernatants, determined by colorimetric assay on CTLL-2 cells as previously described (36) . The presence of IL-1 in the assay supematants has no effect on the indicator cells (36) , and the addition of forskolin did not interfere with the quantitative detection of IL-2 in a control experiment (after adjustment to 10 pLM forskolin, a sample with 450 U of IL-2 per ml gave a titer of 530 U of IL-2 per ml in this assay; E. V. Rothenberg, unpublished data).
RESULTS
IL-1 is a costimulus for IL-2 expression by phorbol esterand ionophore-treated EL4.E1 cells. The EL4.E1 thymoma is a convenient murine model for studies of IL-2 gene expression, but it differs from normal THi cells in several ways. First, it is responsive to TPA alone. A Ca2+ costimulus elicits higher levels of IL-2 but is not required. Second, unlike normal mature T cells (35) , it shows synergy between IL-1 and TPA + A23187. These features are illustrated in Table 1 , which presents typical yields of IL-2 from EL4.E1 cells after 20 h of stimulation under different conditions. The addition of calcium ionophore generally increased the levels of IL-2 relative to those elicited by TPA alone, to a maximum level that could not be surpassed by increasing the doses of TPA + A23187 (data not shown). The further addition of IL-1, however, resulted in even higher levels of IL-2 secretion. Nevertheless, IL-1 alone did not stimulate any detectable production of IL-2. Thus, the effect of IL-1 in these cells was to potentiate the effects of the TPA and A23187 stimuli on IL-2 synthesis. Such a potentiation could operate at pretranscriptional, posttranscriptional, or posttranslational levels. To dissect the basis for these differences in cumulative IL-2 synthesis over 20 h, we examined the time course of IL-2 RNA accumulation.
The accumulation of IL-2 transcripts in EL4.E1 cells stimulated with TPA + A23187 alone was rapid and bimodal ( and by 18 h IL-1 ceased to augment the level of steady-state IL-2 mRNA (Fig. 1A, lanes 9 to 12) . The early increase and later loss of IL-2 RNA makes it likely that IL-1 costimulation increases the transcription rate but not RNA stability or translational efficiency.
No IL-2 mRNA was detected when EL4.E1 cells were stimulated for 5 h with 20 U of IL-1 per ml in the absence of TPA, alone or in combination with 37 ng of A23187 per ml (not shown). This inability to respond to IL-1 plus ionophore is in contrast to results reported by others for several IL-1-independent cell lines (43, 47) , possibly because of the lower concentration of ionophore used here (37 ng/ml = 70 nM, compared with 250 to 500 nM). The failure of IL-1 to substitute for TPA suggests that it cannot duplicate the effects of TPA on protein kinase C.
Costimulatory effects of IL-1 are mediated through the IL-2 gene promoter. To determine whether the IL-2 gene promoter was responsible for mediating this positive effect, we used a series of pIL2-CAT plasmids that contains various lengths of IL-2 5'-flanking DNA, including the transcriptional start site, driving expression of CAT (30) . In this way we could assay transcriptional initiation without concern for regulatory variations in mRNA stability (22) since, unlike authentic IL-2 mRNA, the CAT 3' untranslated region does not contain the AUUUA motifs that target lymphokine transcripts for rapid degradation (33, 38) . Note that the CAT assay measures the translation product of the induced RNA, not the RNA directly.
Transfection experiments using IL2-CAT plasmids suggest that IL-1 can increase the rate of transcription from the IL-2 gene promoter, even in cells optimally stimulated with TPA and ionophore. Several pIL2-CAT plasmids were transfected into EL4.E1 cells along with pRSV-CAT as a positive control. CAT activity was measured after 5, 12, and 18 h of stimulation with TPA and A23187 in the presence and absence of IL-1 ( Fig. 1B and 2) . A CAT assay of cells transfected with pIL2(-2800) is shown in Fig. 1B . Expression of the transfected IL-2-CAT gene required an appropriate inductive signal because unstimulated cells contained no enzyme activity (Fig. 1B, lanes 1, 5, and 9) . Thus, even when introduced as a naked DNA template, the IL-2 gene promoter was not promiscuously transcribed in these cells. EL4.E1 transfectants stimulated with TPA plus A23187 contained easily detectable CAT activity at 5 h (Fig. 1B, lane 2), which would be expected if the peak in endogenous IL-2 mRNA seen at this time resulted from transcriptional activation of the IL-2 gene promoter. CAT activity in these cells continued to rise over the next 13 h, reaching a maximum at 18 h, the latest time examined. This increase in CAT activity occurred even as the steady-state level of endogenous IL-2 mRNA dropped (Fig. 1A) , possibly indicating greater stability of the IL-2-CAT mRNA.
The addition of IL-1 to the stimulation regimen had two dramatic effects. First, cells stimulated in the presence of IL-1 contained up to 2.5 times as much CAT activity per cell at 5 h as did those stimulated with TPA and A23187 alone (Fig. 1B, lanes 1 to 4, and Fig. 2A ). This effect was IL-1 dose dependent because the enhancement was greater with 20 than with 2.5 U/ml. Second, the increase was transient, like the effect on endogenous IL-2 mRNA. Not only did IL-1 completely cease to enhance the steady-state level of IL-2 mRNA at 18 h (Fig. 1A, lanes 10 to 12) , it also ceased to increase the amount of CAT activity per cell. In fact, CAT activity induced in the presence of IL-1 was now at least 60 to 70% lower than in cells stimulated without IL-1 ( Fig. 2A) (see below and Table 3 ). By contrast, the early enhancement of CAT expression from the IL-2 gene promoter was promoter specific. Expression of pRSV-CAT in stimulated EL4.E1 cells was not affected by the presence of IL-1 when examined after 3 or 5 h of stimulation (unpublished data). This result suggests that at later times, IL-1 caused a general decrease in CAT expression, possibly via reduced translational efficiency, which was distinct from its promoterspecific transcriptional enhancing effects seen at 5 h. Fig. 2B . These cells showed much slower kinetics of expression of pIL2-CAT plasmids than did EL4.E1 cells. No activity was detected at 5 h even in the presence of 20 U of IL-1 per ml. Cells had begun to express by 12 h, and CAT activity was still rising by 18 h. However, no significant effect, early or late, could be attributed to IL-1. These results provide evidence that surface expression of a canonical IL-1R is a prerequisite for the IL-1 effects that we have described. It is thus unlikely that the effects seen in EL4.E1 cells are due to the type of phosphatidylcholine hydrolysis reported to occur in Jurkat cells (34) .
(ii) cAMP. It has been shown that IL-1 can utilize cAMP as an intracellular second messenger in a number of non-T-cell lines (42) . Our results argue against a simple cAMP elevation mechanism as the pathway for IL-1 costimulation in EL4.E1 cells. First, IL-1 costimulation had minimal effects on cAMP levels in these cells (Table 2) . Second, the effects of 20 U of IL-1 per ml and 10 ,uM forskolin were clearly different ( Table  3) . Expression of pRSV-CAT was enhanced at 18 h with forskolin but inhibited with the concentration of IL-1 used here. Whereas expression of pIL2(-321) was depressed at 18 h by both IL-1 and forskolin, the 5-h results clearly demonstrated the dissimilarity of these two stimuli. Forsko- Fig. 2A make it unlikely that far-upstream sequences are required. When normalized for maximal levels of CAT activity, the kinetics of IL-1 costimulation for pIL2(-321), pIL2(-1890), and pIL2(-2800) were virtually superimposable ( Fig. 2A) . Thus, the degrees of both the 5-h enhancement and the 18-h suppression were unaffected by IL-2 5'-flanking sequences extending upstream of -321. It should be noted, however, that the absolute amount of CAT activity per cell at each time point was higher with pIL2(-1890) and pIL2(-2800) than with pIL2(-321), in accord with our previously reported results (30 quences from -66 to -90, is the constitutive Oct-1 protein, which also appears to bind sequences between -240 and -250 (10) . Factors whose binding activity is known to be dependent on cellular activation bind at -264 to -284 (NFAT-1) and -196 to -205 (NF-KB or a close relative) (5, 17, 39) . In addition, there are two potential sites for the binding of the canonical TPA-response factor AP-1 (2), although neither contains a perfect consensus sequence. One, from -186 to -195 (AP-1D), has been proposed as a critical site for IL-1 effects in another cell line (26) . The other, from -145 to -153 (AP-1p), has been shown to bind a purified AP-1 factor (37).
To dissect the mechanism of IL-1 costimulation of EL4.E1 cells, we focused on the four sites for potentially inducible factors: NFAT-1, NF-KB, AP-1D, and AP-1p. Synthetic double-stranded oligonucleotides containing these sites as found in the murine IL-2 gene were used in gel retardation assays to detect DNA-binding proteins in nuclear extracts from EL4.E1 cells after different types of stimulation. Typical results, representative of four to seven independent analyses, are presented in Fig. 3 and 4 . A summary is provided in Table 4 .
Four distinct binding specificities. Confirmation of the distinct specificities of these factors is presented in Fig. 3 .
The binding of NFAT-1 was highly sensitive to competition with its homologous target sequence and impervious to competition with the other oligonucleotides used (Fig. 3A) . Figure 3B similarly confirms the specificity of the NF-KB complexes and their ability to be competed for by a longer IL-2 DNA fragment (-148 to -217) that contains this site. We routinely observed a doublet of complexes binding the NF-KB site, both of which appear specific by competition analysis. Only the upper band was strongly induction dependent, however, and in the text that follows we will use "NF-KB" to refer only to this slower-migrating species.
The factors that bind to the two AP-1 sites are not identical, although their target sites are of related sequence. This conclusion was confirmed by the cross-competition analysis shown in Fig. 3C . First, the two complexes had different mobilities (compare lanes 7 and 8). Second, it is clear that they had different binding preferences. Both were legitimately capable of binding a commercial consensus AP-1 oligonucleotide (Fig. 3C, lanes 5 and 13) , and neither was detectably competed for by the NF-KB site oligonucleotide (lanes 6 and 14) . However, while the AP-1P oligonucleotide competed for the complex binding its homologous sequence (lanes 1 and 2) , it did not compete for the AP-1D complex (lanes 9 and 10) . Correspondingly, the AP-1D oligonucleotide showed homologous competition (lanes 11 and 12) but did not compete for the AP-lp complex (lanes 3 and 4). The quantitative reciprocity of these effects, as measured at 100-and 200-fold molar excess, rules out the trivial explanation that the two factors had identical specificities but were present at different concentrations in the nuclear extract. These results show that the two AP-1 factors are distinct both in size and in specificity. As discussed below, they are also distinct in regulation.
Constitutive factors. Two of the factors detected by these assays appeared to be expressed constitutively in the EL4.E1 thymoma cells. One, unexpectedly, was NFAT-1. A complex of the expected mobility (indicated by an arrow in Fig. 4A ) was highly inducible in Jurkat cells (Fig. 4A , lanes VOL. 10, 1990 ---* m,d, :O-06 i. ---, I., 1 and 2). However, the corresponding complex was present at indistinguishable levels in nuclear extracts from our subline of EL4.E1 cells, whether or not they were stimulated and regardless of the stimulation conditions used (Fig. 4A , lanes 4 to 9). This complex appeared unlikely to represent a spurious DNA-binding activity, since it was specific by the competition assays in Fig. 3 but quantitatively unaffected by increasing the concentration of nonspecific competitor (Fig.  4A, lanes 3 and 6) . Thus, although the NFAT-1 site appeared essential for expression, on the basis of our deletion studies, the presence of its binding factor was not sufficient to support IL-2 expression.
The other factor present at unchanged levels was the complex of well-defined mobility binding the AP-1D site (Fig.  4C ). This factor exhibited slight fluctuations in concentration in different samples, but no reproducible increase was observed upon stimulation under any conditions (Table 4 ). In fact, in some experiments there was an indication that its concentration diminished in stimulated cells. The possibility that it might exert a negative regulatory effect is under further study. Inducible factors. Only two of the candidate inducible factors showed increased DNA binding in response to induction. These were NF-KB (Fig. 4B ) and the factor binding the AP-lp site (Fig. 4D ). In agreement with the ability of EL4.E1 cells to make IL-2 in response to TPA alone (Table 1) , both were activated in cells stimulated with TPA alone (Fig. 4B  and D, lanes 2) . The further addition of A23187 up regulated both binding activities in most experiments, in accord with its effect on IL-2 production (Table 1) , although the extents of up regulation did not match precisely ( Fig. 4B and D; compare lanes 2 and 4). The binding activities of both factors, however, were reproducibly enhanced further by addition of IL-1, which consistently yielded the highest levels observed of both complexes ( Fig. 4B and D, lanes 5 ). This result was not due to additive activation of these factors by IL-1 and by TPA + A23187, for in most experiments IL-1 alone induced little or no binding activity of either type (compare lanes 3 in Fig. 4B and D) . Thus, while IL-1 was only marginally and irreproducibly capable of activating either binding factor alone, it was a potent enhancer of the stimulating capacity of A23187 and TPA.
Summary. The results of multiple analyses of these four factors are collated in Table 4 . Overall, these data agree plausibly with the IL-2 titers reported in Table 1 , if it is assumed that all four factors are required for optimal promoter activity. The surprising, constitutive expression of NFAT-1 in this subline of cells, and possibly that of the AP-1D binding factor a well, may simply provide the biochemical explanation For the unique ability of EL4.E1 cells to express IL-2 in response to TPA alone. Nevertheless, this set of factors may not be sufficient to account for all regulatory modulation of IL-2 gene expression in EL4.E1 cells. As shown previously (Novak and Rothenberg, in press; Tables 1 and 3), 10' M forskolin inhibits IL-2 induction by two-to threefold under these conditions. It is therefore surprising that forskolin, when added to TPA and A23187, induced effects on these DNA-binding proteins that were very similar to those of IL-1 (Fig. 4A, lane 9 ; Fig. 4B to D, lanes 6). While in several experiments the addition of forskolin appeared to decrease NF-KB expression selectively (data not shown), this effect was often modest (e.g., Recent work by Shirakawa and colleagues has shown that IL-1 can utilize cAMP as an intracellular second messenger for the induction of K immunoglobulin light-chain synthesis in the mouse pre-B-cell line 70Z/3 (42) . In these cells, IL-1-mediated induction coincides with the activation of a protein that can bind to the NF-KB consensus site in the 5'-flanking region of the K-chain genes (40) . NF-KB is not the only transcription factor implicated in IL-1 effects, however. IL-1 can also induce transcription of the c-jun proto-oncogene, which encodes a component of AP-1, in the mouse IL-1-dependent T-cell line LBRM-331A5 (26) . In that cell line, expression of a linked reporter gene from the human IL-2 promoter required an intact AP-1 site at -185 relative to the transcriptional start site. However, the deletions tested which removed this site also removed the NF-KB site centered at -200. Therefore, the resulting loss of promoter function (26) cannot be attributed unequivocally to loss of this distal AP-1 site. In fact, deletion analysis of the human IL-2 gene promoter has not demonstrated an important role for this AP-1 site in vivo (8) . Footprint analysis of the mouse IL-2 promoter has led to the same conclusion (37) .
In several respects, our results are in agreement with these previous reports. Thus, our data support the interpretation that one mediator of the IL-1 effect may be NF-KB or a related factor (31, 40) . The addition of IL-1 as a costimulus invariably augmented NF-KB binding activity over that induced by the cocktail of TPA and A23187, and in some experiments (e.g., Fig. 4) we could even detect enhanced NF-KB binding after stimulation with IL-1 alone. As expected if IL-1 activated NF-KB, it also enhanced the induction of IL-2 receptor a-chain transcripts in the EL4.E1 cells (T. J. Novak and E. V. Rothenberg, unpublished results). Even the failure of IL-1 to affect IL-2 gene promoter activity in Jurkat cells is also consistent with its working through NF-KB, since in these cells IL-1 does not induce appearance of this DNA-binding protein (31) . The resulting implication that NF-KB may be rate limiting for IL-2 induction is in accord with published evidence that mutation of the NF-KB site depresses IL-2 gene promoter function, relative to wild type, in optimally stimulated cells (17) .
In contrast to other cell types (41, 42) The effects of IL-1 would then be additive with those of the phosphoinositide pathway agonists, at the level of the DNAprotein contacts in chromatin. Another possibility is that the ability of A23187/TPA to activate these DNA-binding proteins is itself modulated by an intracellular gating function that is subject to IL-1 regulation. In this case, IL-1 need not induce any DNA-binding protein activities by itself in order to be a potent regulator of the efficiency with which the major activating pathway mobilizes gene expression. While too few factors have yet been examined to confirm or rule out the first mechanism, several of our findings lend plausibility to the second. First, IL-1 alone is strikingly poor at effecting any increase or decrease in the binding activity of any of the factors studied here. In EL4.E1 cells, it is far more potent as a costimulus than as a stimulus (see, e.g., Table 4 ). Second, the factors that IL-1 coactivates thus far appear to be only those that are activated in any case by A23187 and TPA. Third, our survey of IL-1 effects on the expression of IL-2 promoter constructs with widely differing numbers of positive and negative modulatory sites (30) indicates that all expressible constructs are affected in parallel. Thus, IL-1 may act in these cells by enhancing the potency of A23187 and TPA as inducing agents, its signals converging with the phosphoinositide pathway before the activation of the specific DNA-binding proteins.
The mechanism of IL-1 costimulation may help to illuminate key stages in the development of T-cell functional competence. We have previously reported that immature thymocytes can activate the IL-2 gene, but only subject to an absolute requirement for IL-1 costimulation. The locus of the IL-1 effect may thus identify a stage-specific block to the exercise of function in immature cells which is later overcome by the complex physiology of positiv,e~selection in the thymus. Work is now under way to explo#e this possibility.
